Comparisons of serum CTLA-4 levels between treated and Untreated SCLC and NSCLC Patients
Journal of the Faculty of Medicine Baghdad · 01.07.2026 · 68 (2) · 159-168
DOI: 10.32007/jfacmedbaghdad3260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Faculty of Medicine Baghdad, online erschienen am 01.07.2026. Verfasst von Zinah Al-Hayali und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer and major causes of cancer-related death worldwide.
Objectives
To compare serum cytotoxic T-lymphocyte-associated antigen 4 levels between treated and untreated patients with small cell lung cancer and non-small cell lung cancer, and healthy controls.
Methods
This case-control study was conducted at the Oncology Teaching Hospital, Baghdad, Iraq, from December 2024 to June 2025. The study included 180 participants: 24 patients with small cell lung cancer, 96 with non-small cell lung cancer, and 60 healthy controls. Serum cytotoxic T-lymphocyte-associated antigen 4 levels were measured using enzyme-linked immunosorbent assay, and complete blood count parameters were measured using an automated hematology analyzer.
Results
Cytotoxic T-lymphocyte-associated antigen 4 levels differed significantly among the control, small cell lung cancer, and non-small cell lung cancer groups (p = 0.02), with higher levels in small cell lung cancer and lower levels in non-small cell lung cancer than controls. No significant differences were observed between treated and untreated patients in either group. Cytotoxic T-lymphocyte-associated antigen 4 levels were significantly associated with Programmed death-ligand 1 categories in treated non-small cell lung cancer patients (p = 0.01), but not in untreated patients (p = 0.12). Complete blood count parameters differed significantly among the study groups, suggesting systemic inflammatory changes. Serum cytotoxic T-lymphocyte-associated antigen 4 showed limited diagnostic performance.
Conclusion
Cytotoxic T-lymphocyte-associated antigen 4 levels were significantly associated with Programmed death-ligand 1 expression in treated patients. Complete blood count, cytotoxic T-lymphocyte-associated antigen 4, and Programmed death-ligand 1 may provide useful information on the inflammatory and immunological status of lung cancer patients, but further studies are needed to confirm their clinical significance.
Zitieren
APA
Al-Hayali, Z., & Al-Humairi, R. (2026). Comparisons of serum CTLA-4 levels between treated and Untreated SCLC and NSCLC Patients. Journal of the Faculty of Medicine Baghdad, 68(2), 159-168. https://doi.org/10.32007/jfacmedbaghdad3260
Vancouver
Al-Hayali Z, Al-Humairi R. Comparisons of serum CTLA-4 levels between treated and Untreated SCLC and NSCLC Patients. Journal of the Faculty of Medicine Baghdad. 2026;68(2):159-168. doi:10.32007/jfacmedbaghdad3260
BibTeX
@article{AlHayali2026,
author = {Al-Hayali, Zinah and Al-Humairi, Rasha},
title = {Comparisons of serum CTLA-4 levels between treated and Untreated SCLC and NSCLC Patients},
journal = {Journal of the Faculty of Medicine Baghdad},
year = {2026},
volume = {68},
number = {2},
pages = {159--168},
doi = {10.32007/jfacmedbaghdad3260}
}
EUVIMED